Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Visitors trend2W10W9M
2.2400-0.0300 (-1.32%)
At close: 04:00PM EST
2.2300 -0.01 (-0.45%)
After hours: 04:37PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close2.2700
Open2.2800
Bid2.2500 x 1400
Ask2.3000 x 2200
Day's Range2.2100 - 2.3156
52 Week Range2.0000 - 6.6200
Volume213,338
Avg. Volume121,721
Market Cap64.981M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-1.7220
Earnings DateMar 13, 2023 - Mar 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LIFE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • aTyr Pharma, Inc.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Rating
    Fair Value
    Economic Moat
    11 hours agoMorningstar
View more
  • GlobeNewswire

    aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference

    Symposia presentation to highlight significant advancements in understanding of efzofitimod’s MOA Poster presentation analyzing exposure-efficacy of efzofitimod further supports clinical proof-of-concept SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data on the me

  • GlobeNewswire

    aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

    Patent highlights potential benefit of efzofitimod as a combination therapy for IPF standard of care.SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Patent Office (EPO) has provided a Notice of Allowance for a patent covering methods for the use of histidyl-tRNA synthetase (HARS) Fc fusion pr

  • GlobeNewswire

    European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis

    Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in EuropeSAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug designation for the company’s lead therapeutic candidate, efzofitimod, for the treatment of sarcoidosis based on the opinion of

Advertisement
Advertisement